Medite Cancer Diagnostics logo

Medite Cancer Diagnostics(OTC) MDIT

Market Cap$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-50%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Medite Cancer Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-05
Medite Cancer Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-04
1 month+0%USD 0.002026-09-04
3 month+0%USD 0.002026-06-08
Year to date+0%USD 0.002025-12-18
1 year+0%USD 0.002025-09-24
3 year+0%USD 0.002023-09-29
5 year-50%USD 0.002021-09-27
Since inception-100%USD 100.001998-12-07

Medite Cancer Diagnostics Financials at a Glance

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-16.76 (Low)

Price

$0.00

Volume

2,026

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2025

MDIT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medite Cancer Diagnostics

Medite Cancer Diagnostics, Inc. is a medical technology company focused on developing, manufacturing, and marketing innovative solutions for cancer detection and diagnosis. The company specializes in molecular biomarkers and medical devices that aid in the assessment of cancerous and precancerous conditions.

Products and Services
  • USE 33: Ultrasonic decalcification instrument for controlled temperature processing
  • SoftKit: Device for self-collection of samples for female health assessment
  • Robotic systems: Advanced tissue processing and staining instruments
Growth Outlook
  • Expansion into international markets, including Europe and North Africa
  • Increasing demand for cancer diagnostics and related medical technologies
  • Focus on innovative product development to enhance market position
Financial Highlights
  • Market capitalization stands at approximately $8,672
  • Trailing twelve months (TTM) revenue of $0.0001 per share
  • Current ratio of 0.92 indicates liquidity management challenges
Medite Cancer Diagnostics, Inc. operates in a critical sector, providing essential tools for cancer diagnosis. The company's product offerings, including advanced robotic systems and self-collection devices, position it well within the growing healthcare market. The focus on international expansion and innovative product development suggests a proactive approach to capturing market share. However, financial metrics indicate challenges, particularly in liquidity, which may require strategic management to enhance operational efficiency. Overall, Medite Cancer Diagnostics presents a unique opportunity within the medical technology landscape, appealing to investors interested in the healthcare sector.
AI Generated • Sep 28, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Headquarters

Orlando, FL 32832, US

MDIT Financials

Key Financial Metrics (TTM)

Gross Margin

-1.92%

Operating Margin

-95.11%

Net Income Margin

-99.97%

Return on Equity

-98.90%

Return on Capital

-58.02%

Return on Assets

-42.69%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

86.20M

Volume

2.03K

Avg. Volume

31.662

Financials (TTM)

Gross Profit

-$131.00K

Operating Income

-$6.48M

EBITDA

-$6.19M

Operating Cash Flow

-$2.59M

Capital Expenditure

-$134.00K

Free Cash Flow

-$2.72M

Cash & ST Invst.

$490.00K

Total Debt

$5.39M

Medite Cancer Diagnostics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CEVECeres Ventures, Inc.
$0.00+0.00%
RCARRenovaCare, Inc.
$0.00+0.00%
ASFXAmerican Scientific Resources, Incorporated
$0.00+0.00%
FIORFFiore Cannabis Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.29+5.33%
BKLCBny Mellon ETF Trust - Bny Mellon Us Large Cap Core Equity ETF
$49.57-0.33%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$18.69-6.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$149.83-5.71%

Questions About MDIT

What is the current price of Medite Cancer Diagnostics?

Medite Cancer Diagnostics is trading at $0.00 per share.

What is the 52-week range for Medite Cancer Diagnostics?

Over the past 52 weeks, Medite Cancer Diagnostics has traded between $0.00 and $0.00.

How much debt does Medite Cancer Diagnostics have?

Medite Cancer Diagnostics total debt is unavailable.

How much cash does Medite Cancer Diagnostics have on hand?

Medite Cancer Diagnostics does not have cash on hand data available.

What is Medite Cancer Diagnostics’s dividend yield?

Medite Cancer Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services